How much funding has Adnexus Therapeutics raised?

Adnexus Therapeutics has raised $42.5M in total funding, most recently a Series C round.

Who are Adnexus Therapeutics's investors?

Adnexus Therapeutics's investors include Bristol Myers Squibb, HBM BioVentures, Venrock, Mayfield Fund, Benchmark, Tenaya Capital.

When was Adnexus Therapeutics founded?

Adnexus Therapeutics was founded in 2003.

Where is Adnexus Therapeutics headquartered?

Adnexus Therapeutics is headquartered in Waltham, Massachusetts, United States.

What industry is Adnexus Therapeutics in?

Adnexus Therapeutics operates in Biotech, Healthcare.

How many employees does Adnexus Therapeutics have?

Adnexus Therapeutics has 1-10 employees.

Adnexus Therapeutics

Closed

Pioneering Adnectin therapeutics based on human fibronectin.

Waltham, United States · Founded 2003 · $42.5M raised

Biotech

Healthcare

Headquarters: Waltham, Massachusetts
Employees: 1–10
Founded: 2003
Business Model: B2B

Website: adnexus.com
Total Funding: $42.5M
Last Round: $15.5M Series CAug 2007
Rounds: 2

About

Adnexus Therapeutics, founded in 2003 and headquartered in Waltham, Massachusetts, was a biopharmaceutical company that pioneered Adnectin therapeutics — engineered variants of the tenth type III domain of human fibronectin. Adnectins were designed as a new protein scaffold platform to generate highly potent, specific, and stable therapeutic agents with favorable half-life and high-yield E. coli production. The company's lead oncology compound, CT-322, was an Adnectin inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) developed as an anti-angiogenic cancer therapy. Adnexus was founded by Flagship Pioneering (then Flagship Ventures) and acquired by Bristol-Myers Squibb in September 2007 for approximately $430 million, making it one of the largest biotech acquisitions of that year.

Summary

Adnexus Therapeutics is a Biotech company based in Waltham, United States, founded in 2003. It has raised $42.5M in total across 2 rounds, most recently a $15.5M Series C round in Aug 2007. Investors include Bristol Myers Squibb, HBM BioVentures and Venrock.